Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - askorbinska kislina (vitamin c); cianokobalamin (vitamin b12); folna kislina (vitamin b9); fosfor; holekalciferol (vitamin d3); kalcij; kalcijev pantotenat; nikotinamid; piridoksinijev klorid; riboflavin (vitamin b2); tiaminijev nitrat; vitamin a - obložena tableta - askorbinska kislina (vitamin c) 10 i.e. / 1 tableta  cianokobalamin (vitamin b12)0,0002 i.e. / 1 tableta  folna kislina (vitamin b9)0,04 i.e. / 1 tableta  fosfor10 i.e. / 1 tableta  holekalciferol (vitamin d3)80 i.e. / 1 tableta  kalcij12,5 i.e. / 1 tableta  kalcijev pantotenat1,2 i.e. / 1 tableta  nikotinamid3 i.e. / 1 tableta  piridoksinijev klorid0,3 i.e. / 1 tableta  riboflavin (vitamin b2)0,3 i.e. / 1 tableta  tiaminijev nitrat0,25 i.e. / 1 tableta  vitamin a600 i.e. / 1 tableta; cianokobalamin (vitamin b12) 0,0002 i.e. / 1 tableta  folna kislina (vitamin b9)0,04 i.e. / 1 tableta  fosfor10 i.e. / 1 tableta  holekalciferol (vitamin d3)80 i.e. / 1 tableta  kalcij12,5 i.e. / 1 tableta  kalcijev pantotenat1,2 i.e. / 1 tableta  nikotinamid3 i.e. / 1 tableta  piridoksinijev klorid0,3 i.e. / 1 tableta  riboflavin (vitamin b2)0,3 i.e. / 1 tableta  tiaminijev nitrat0,25 i.e. / 1 tableta  vitamin a600 i.e. / 1 tableta; folna kislina (vitamin b9) 0,04 i.e. / 1 tableta  fosfor10 i.e. / 1 tableta  holekalciferol (vitamin d3)80 i.e. / 1 tableta  kalcij12,5 i.e. / 1 tableta  kalcijev pantotenat1,2 i.e. / 1 tableta  nikotinamid3 i.e. / 1 tableta  piridoksinijev klorid0,3 i.e. / 1 tableta  riboflavin (vitamin b2)0,3 i.e. / 1 tableta  tiaminijev nitrat0,25 i.e. / 1 tableta  vitamin a600 i.e. / 1 tableta; fosfor 10 i.e. / 1 tableta  holekalciferol (vitamin d3)80 i.e. / 1 tableta  kalcij12,5 i.e. / 1 tableta  kalcijev pantotenat1,2 i.e. / 1 tableta  nikotinamid3 i.e. / 1 tableta  piridoksinijev klorid0,3 i.e. / 1 tableta  riboflavin (vitamin b2)0,3 i.e. / 1 tableta  tiaminijev nitrat0,25 i.e. / 1 tableta  vitamin a600 i.e. / 1 tableta; holekalciferol (vitamin d3) 80 i.e. / 1 tableta  kalcij12,5 i.e. / 1 tableta  kalcijev pantotenat1,2 i.e. / 1 tableta  nikotinamid3 i.e. / 1 tableta - multivitamini in kalcij

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - cianokobalamin (vitamin b12); kalcijev pantotenat; nikotinamid; piridoksinijev klorid; riboflavin (vitamin b2); tiaminijev nitrat - filmsko obložena tableta - cianokobalamin (vitamin b12) 0,001 mg / 1 tableta  kalcijev pantotenat5 mg / 1 tableta  nikotinamid25 mg / 1 tableta  piridoksinijev klorid2 mg / 1 tableta  riboflavin (vitamin b2)5 mg / 1 tableta  tiaminijev nitrat4 mg / 1 tableta; kalcijev pantotenat 5 mg / 1 tableta  nikotinamid25 mg / 1 tableta  piridoksinijev klorid2 mg / 1 tableta  riboflavin (vitamin b2)5 mg / 1 tableta  tiaminijev nitrat4 mg / 1 tableta; nikotinamid 25 mg / 1 tableta  piridoksinijev klorid2 mg / 1 tableta  riboflavin (vitamin b2)5 mg / 1 tableta  tiaminijev nitrat4 mg / 1 tableta; piridoksinijev klorid 2 mg / 1 tableta  riboflavin (vitamin b2)5 mg / 1 tableta  tiaminijev nitrat4 mg / 1 tableta; riboflavin (vitamin b2) 5 mg / 1 tableta  tiaminijev nitrat4 mg / 1 tableta; tiaminijev nitrat 4 mg / 1 tableta - vitamini kompleksa b brez dodatkov

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imunski sera in imunoglobulini, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. glej poglavja 4. 4 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

hcs bvba  - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotična sredstva - sekundarno preprečevanje atherothrombotic eventsclopidogrel je navedeno v:izobraževanje odraslih bolnikih, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni. za odrasle bolnike, ki trpijo za akutni koronarni sindrom:non-st segmentu višinskih akutni koronarni sindrom (nestabilna angina pektoris ali ne-q-val, miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. preprečevanje atherothrombotic in thromboembolic dogodkov v atrijska fibrillationin odraslih bolnikov z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke, niso primerni za zdravljenje z antagonisti vitamina k (vka) in ki imajo nizko tveganje krvavitve, clopidogrel je indiciran v kombinaciji s asa za preprečevanje atherothrombotic in thromboembolic dogodkov, vključno z možgansko kap.  for further information please refer to section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplo sklerozo, recidivno-nakazila - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - predkroglomerna limfoma t-celična limfoblastna levkemija - antineoplastična sredstva - nelarabine je indiciran za zdravljenje bolnikov z t-celic acute lymphoblastic levkemijo (t-all) in t-celic lymphoblastic limfom (t-lbl), katerih bolezen ni odgovorila, ali je relapsed po zdravljenju z vsaj dvema kemoterapijo regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.